[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368376-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368376-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","epidemiology-of-burden-of-prostate-cancer-in-iran-during-2009-2019-estimates-from-the-global-burden-of-disease-study-2019","Epidemiology of Burden of Prostate Cancer in Iran during 2009-2019 - Estimates from the Global Burden of Disease Study 2019","","Prostate cancer is the second most common cancer in men and the fifth leading cause of death worldwide. This study investigates the epidemiological situation of incidence, prevalence, and overall burden of prostate cancer in Iran from 2009 to 2019. A descriptive-analytical approach uses Global Burden of Disease 2019 data to quantify provincial incidence, mortality, DALY, YLL, and YLD, with ArcGIS mapping and Pearson correlation to assess links with the Human Development Index.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/epidemiology-of-burden-of-prostate-cancer-in-iran-during-2009-2019-estimates-from-the-global-burden-of-disease-study-2019/368376/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/epidemiology-of-burden-of-prostate-cancer-in-iran-during-2009-2019-estimates-from-the-global-burden-of-disease-study-2019/368376.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on prostate cancer in Iran (2009–2019)?","Question",{"text":63,"@type":64},"To investigate the epidemiological situation of prostate cancer incidence, prevalence, and burden across Iran from 2009 to 2019.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data sources and indicators are used to estimate the burden of prostate cancer?",{"text":68,"@type":64},"The study uses Global Burden of Disease (GBD) 2019 data for each Iranian province, including incidence, mortality, DALY, YLL, and YLD.",{"name":70,"@type":61,"acceptedAnswer":71},"How is the Human Development Index related to prostate cancer incidence in the results?",{"text":72,"@type":64},"Pearson correlation shows a positive and statistically significant correlation between prostate cancer ASIR and the Human Development Index in Iran.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368376,1790697020,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","IJMS  \nVol 50, No 3, March 2025  \nOriginal Article  \nEpidemiology of Burden of Prostate Cancer in Iran during 2009-2019: Estimates from the Global Burden of Disease Study 2019  \nElham Goodarzi1,2 , PhD; Saeed Rajaei Ramesh3 , MD; Sajjad Rahimi Pordanjani4 , PhD; Mahshid Abbasi5 , MD; Fazlollah Fathollahi Shoorabeh6 , PhD  \n1Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khoram abad, Iran;  \n2Social Determinants of Health Research Center, Iran University of Medical Sciences, Tehran, Iran;  \n3Cilinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran;  \n4Department of Public Health, Behbahan Faculty of Medical Sciences, Behbahan, Iran;  \n5 Department of Radiation Oncology, School of Medicine, Lorestan University of Medical Sciences, Khoram abad, Iran;  \n6 Nutrition Health Research Center, School of Medicine, Lorestan University of Medical Sciences, Khoram abad, Iran  \nCorrespondence:  \nFazlollah Fathollahi Shoorabeh, PhD; School of Medicine, Lorestan University of Medical Sciences, Kamalvand, Postal code:  \n33120173, Khoram abad, Iran Tel: +986633120172  \nEmail: [f.fathollahi1363@gmail.com](f.fathollahi1363@gmail.com)  \n[Received: 24 October 2023](Received: 24 October 2023)  \n[Revised: 14 January 2024](Revised: 14 January 2024)  \n[Accepted: 14 February 2024](Accepted: 14 February 2024)  \n\n| \u003Cbr>What’s Known\u003Cbr>• In Iran, prostate cancer is reported as one of the most common cancers.\u003Cbr>• There are varying reports of prostate cancer among men in different regions of Iran.\u003Cbr>\u003Cbr>What’s New |\n| --- |\n| • The distribution of the burden of prostate cancer varies among the provinces. Provinces with a high Human Development Index have a higher incidence rate, possibly attributed to better screening programs in these provinces.\u003Cbr>• The incidence and mortality rates of prostate cancer are increasing in Iran, with the highest incidence, mortality, and burden of prostate cancer being related to Bushehr province. |\n\nAbstract  \nBackground: Prostate cancer (PC) is the second most common cancer in men and the fifth leading cause of death worldwide. The purpose of this study is to investigate the epidemiological situation concerning the incidence, prevalence, and burden of prostate cancer in Iran from 2009 to 2019.  \nMethods: The present research is a descriptive-analytical study. To assess the spatial distribution of prostate cancer, data on the incidence, mortality, Disability-adjusted life years (DALY), Years of Life Lost due to premature mortality (YLL), and Years of Life Lost due to disability (YLD) in each province of Iran from 2009 to 2019 were obtained from the Global Burden of Disease (GBD) 2019 website. The incidence and mortality zoning in Iran was mapped using the ArcGIS 10.3 environment. The two-variable Pearson correlation coefficient was used to analyze the data extracted to study the correlation between PC and the Human Development Index.  \nResults: The highest Age-Standardized Incidence Rate (ASIR) of prostate cancer (40.55 per 100,000), mortality (17.09 per 100,000), YLL (254.1 per 100,000), YLD (23.88 per 100,000), and DALY (277.98 per 100,000) is related to Bushehr province. The results of the Pearson correlation reveal a positive and statistically significant correlation between the ASIR of prostate cancer and the Human Development Index (r=0.651, P=0.0001) in Iran. The highest Percentage of Annual Changes (PAC) in ASIR, Age-Standardized Mortality Rate (ASMR), Age-Standardized Prevalence Rate (ASPR), YLL, YLD, and DALY were related to the provinces of West Azarbayejan (62.9%), Golestan (30.86%), West Azarbayejan (87.66%), Golestan (29.38%), West Azarbayejan (76.95%), and Alborz (31.45%), respectively. Conclusion: The incidence and mortality rates of prostate cancer in all provinces of the country are on the rise. Therefore, screening programs for early detection to reduce the mortality of the disease, and etiology studies to ide","cbCaiqGew7SG4EDb","https://ap.wps.com/l/cbCaiqGew7SG4EDb","pdf",1524389,"English","# What’s Known\n# What’s New\n# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is the main purpose of the study on prostate cancer in Iran (2009–2019)?\",\"answer\":\"To investigate the epidemiological situation of prostate cancer incidence, prevalence, and burden across Iran from 2009 to 2019.\"},{\"question\":\"What data sources and indicators are used to estimate the burden of prostate cancer?\",\"answer\":\"The study uses Global Burden of Disease (GBD) 2019 data for each Iranian province, including incidence, mortality, DALY, YLL, and YLD.\"},{\"question\":\"How is the Human Development Index related to prostate cancer incidence in the results?\",\"answer\":\"Pearson correlation shows a positive and statistically significant correlation between prostate cancer ASIR and the Human Development Index in Iran.\"}]","Epidemiology of Burden of Prostate Cancer in Iran during 2009-2019 - Estimates from the Global Burden of Disease Study 2019 | PDF",1790176603,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5238db31b14cdb7110fc14ce37a9acdd.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8841d8092458a27e10add9c7d6d86549.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9286454fa3eef659073857b46bb931d6.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b35a79d3eaf57476819ee3040a377434.webp",980,1385]